Today, drugs like Ozempic (semaglutide), Wegovy, and Mounjaro (tirzepatide) are being prescribed and demanded for obesity, cardiometabolic risk, and even aesthetic weight loss
29 Another valuable study would be a prospective randomized clinical trial with well-designed primary ocular outcomes comparing the GLP-1/GIP agonists to another diabetes drug class, such as the SLGT inhibitors, which has the same target hemoglobin A1c reduction in both treatment arms
Wegovy and Zepbound are drugs approved by the Food and Drug Administration (FDA) for weight management
Introduction Le BPC-157 (Body Protection Compound-157) est l'un des peptides les plus tudis dans le domaine de la mdecine rgnrative
48 However, another study reported opposite results regarding the association between adropin and hypertension
Originally developed to treat type 2 diabetes, it gained significant attention for its secondary benefit: weight loss